ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PTCT vs ERAS // DIVIDEND YIELD & FCF PAYOUT SAFETY

PTC Therapeutics Inc. (NASDAQ) VS. Erasca Inc. (NASDAQ) • 15-METRIC TALLY: PTCT 3 — ERAS 2
■ METRIC PARITY
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTCT VS. ERAS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PTCT ERAS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% -35.00% +120.00 PTCT /roic <GO>
EV/EBITDA & P/E Valuation 6.5x — — TIE /valuation <GO>
Free Cash Flow Yield 13.05% -1.82% +14.87 PTCT /fcf-yield <GO>
Operating Margin 50.10% — — TIE /operating-margins <GO>
Net Profit Margin 39.50% — — TIE /net-margins <GO>
Revenue Growth (YoY) 114.50% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.73 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 9/9 3/9 +6.00 PTCT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.2 45.3 -2.10 ERAS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.15 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 6.6x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $5.01B $5.02B -$8.9M ERAS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PTCT REV ERAS REV PTCT GROSS % ERAS GROSS % PTCT FCF ERAS FCF
FY 2025 $1.73B $394.5M — — $702.3M -$95.6M
FY 2024 $806.8M $502.8M — — -$114.2M -$109.5M
FY 2023 $937.8M $396.3M — — -$200.6M -$101.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTCT // BETA 1.15
ERAS // BETA —